Connor, Clark & Lunn Investment Management (CC&L)
XENE icon

Connor, Clark & Lunn Investment Management (CC&L)’s Xenon Pharmaceuticals XENE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
+19,439
New +$896K ﹤0.01% 1130
2023
Q1 		– Sell
-5,799
Closed -$229K – 1481
2022
Q4 		$229K Buy
+5,799
New +$211K ﹤0.01% 1032
2022
Q2 		– Sell
-7,658
Closed -$234K – 1218
2022
Q1 		$234K Buy
+7,658
New +$229K ﹤0.01% 921

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return